Imogen Farrow
Imogen tracks uplistings, small IPOs, and exchange compliance across the micro-cap market, covering how the smallest issuers reach and keep senior listings.
Articles by Imogen Farrow
BioStem Technologies Graduates to Nasdaq as the Small-Cap Listing Window Stays Open
The Florida tissue-allograft maker began trading on the Nasdaq Capital Market on August 7, joining a 2026 new-listings calendar that is running ahead of last year's pace.
First Phosphate Skips a Rung: ADR Uplisting Lands the LFP Developer on the Nasdaq Global Market
The Quebec-focused phosphate company moved its American Depositary Receipts from OTCQX to the Nasdaq Global Market on August 10 under the ticker PHOS — a cross-border listing route that raised no new capital and issued no new shares.
Ticketplus Squeezes Onto NYSE American at a Deep Haircut as the Small-IPO Window Stays Open — but Picky
The Chilean ticketing platform cut its valuation by more than a third to get its $15 million deal done, the same week larger biotech IPOs priced upsized offerings and four SPACs hit the tape.
HengHong Triples Its Deal Size as the Nano-Cap IPO Calendar Fills Ahead of Summer's Close
A Hainan pharmaceutical distributor upsized a $10 million offering toward $33 million, while a Chinese copper-foil maker and a $75 million Nasdaq deal round out what underwriters are calling the last window before Labor Day.